NOTES TO THE FINANCIAL STATEMENTS — NOTE 25

25. Employee remuneration
  Equity-settled share-based employee remuneration

On 1 January 2014, the group implemented a long-term employee incentive scheme, the conditional unit plan (CUP), which consists of two components — performance shares and retention shares. Both the performance and retention components of the scheme are settled with Hyprop shares.

The terms and conditions of the long-term employee incentive scheme were approved at the Hyprop annual general meeting on 5 December 2013.

25.1 Performance shares
  In terms of the CUP, fully paid awards are made on an annual basis, comprising performance shares and retention shares.

The split between performance shares and retention shares is 70%:30% for all participants.

The performance conditions for the shares allocated as performance shares are as follows:
Growth in distribution per share relative to a peer group (weighting 40%)
Share price performance relative to a peer group (weighting 40%)
Strategic component, which will be determined by the remuneration committee in line with the prevailing circumstance and projects at the time of the award (weighting 20%).

Each of the performance conditions will be measured over a three-year performance period. Participants must be employed until the end of the vesting period to be eligible for the award.

25.2 Retention shares
  Retention shares vest after five years, provided the participant is still employed by the group.
25.3 Reconciliation of shares allocated in terms of the CUP
  Number of 
performance 
shares 
  Number of 
retention 
shares 
 
Unvested at 30 June 2014 107 563    46 100   
Granted 110 422    47 324   
Forfeited (3 368)   (1 443)  
Unvested at 30 June 2015 214 617    91 981   
Granted 78 282    33 549   
Forfeited (7 955)   (3 757)  
Vested (1 356)   (234)  
Unvested at 30 June 2016 283 588    121 539   

  Performance
shares
  Retention
shares
 
Tranche 1        
Grant date 1 January 2014   1 January 2014  
Vesting period ends 31 December 2016   31 December 2018  
Fair value of options at grant date R61,50   R54,77  
Share price at grant date R76,50   R76,50  
The inputs used in the measurement of the fair value at grant date were as follows:        
Expected life 3 years   5 years  
Volatility 20,00%   20,00%  
Interest-free rate after taxation of 28% 5,75%   5,75%  
Dividend yield 5,79%   5,79%  
Tranche 2        
Grant date 1 July 2014   1 July 2014  
Vesting period ends 30 June 2017   30 June 2019  
Fair value of options at grant date R65,55   R58,12  
Share price at grant date R79,51   R79,51  
The inputs used in the measurement of the fair value at grant date were as follows:        
Expected life 3 years   5 years  
Volatility 20,00%   20,00%  
Interest-free rate after taxation of 28% 5,88%   5,88%  
Dividend yield 6,01%   6,01%  
Tranche 3        
Grant date 1 July 2015   1 July 2015  
Vesting period ends 30 June 2018   30 June 2020  
Fair value of options at grant date R105,76   R96,68  
Share price at grant date R121,00   R121,00  
The inputs used in the measurement of the fair value at grant date were as follows:        
Expected life 3 years   5 years  
Volatility 20,00%   20,00%  
Interest-free rate after taxation of 28% 5,97%   5,97%  
Dividend yield 4,49%   4,49%  

The executive directors were allocated the following percentages of the total shares allocated:

  Pieter Prinsloo
(CEO)
  Laurence Cohen
(FD)
 
Tranche 1        
Performance shares 19%   10%  
Retention shares 19%   10%  
Tranche 2        
Performance shares 20%   11%  
Retention shares 20%   11%  
Tranche 3        
Performance shares 20%   11%  
Retention shares 20%   11%  
The charge to the statement of profit or loss and other comprehensive income for the year ended 30 June 2016 amounted to R9,9 million (2015: R6,7 million). As the above are equity-settled shared-based payments, the accounting treatment recognises the share-based payments in profit or loss on a straight-line basis over the vesting period, with a corresponding credit to equity.

NOTES TO THE FINANCIAL STATEMENTS — NOTE 25